# Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab

> **NCT00536640** · PHASE2 · COMPLETED · sponsor: **Aktion Bronchialkarzinom e.V.** · enrollment: 224 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Bevacizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00536640
- **Lead sponsor:** Aktion Bronchialkarzinom e.V.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-08
- **Final completion:** 2012-05
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2013-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536640, "Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00536640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*